

COPD - Pharmacotherapy Overview

Although COPD is a chronic, largely irreversible disorder, pharmacotherapy may improve the quality of life in some patients. The chart below outlines the pharmacological management of COPD according to the most recent guidelines.ⁱ

Severity of Symptoms	Drug Class	Medication	Usual Daily Dosage Range*	Comments	
Increasing Severity of Symptoms →	Intermittent	(see below)	PRN		
	Regular symptomatic	Anti-cholinergics	Ipratropium 20ug / inhalation <i>Atrovent</i>	2-4 puffs TID-QID	♦considered 1 st line as better bronchodilation, ↓ side effects vs SABAs
		SABA	Fenoterol 100ug <i>Berotec</i>	2-4 puffs TID-QID prn	♦hypokalemia may result with high doses
			Salbutamol 100ug <i>Ventolin</i>		
			Terbutaline 0.5mg <i>Bricanyl</i>	2-4 puffs TID prn	
	Combination Therapy	Ipratropium 20ug + Salbutamol 100ug <i>Combivent</i>	2-4 puffs TID-QID	♦some studies show additive effects; others show no benefit over optimal doses of single agent	
	Moderate Using lots of SAB2 or nocturnal/early morning symptoms	LABA	Formoterol 6-12ug Turbuhaler <i>Oxeze</i>	1 dose BID	♦Aim for low therapeutic level (55-85umol/L) ♦many DIs
			Formoterol 12ug DPI <i>Foradil</i>	12ug cap inhal BID	
			Salmeterol MDI <i>Serevent</i>	ii puffs BID	
			Salmeterol Diskus <i>Serevent</i>	1 inhal BID	
Theophylline		various SR products ♦may improve dyspnea, exertional endurance, and quality of life for some pts ♦useful for ↓ nocturnal decline in pulmonary function and associated morning symptoms	400-800mg /day		
Patient symptomatic &/or limited in daily activities despite above.	Oral corticosteroid trial	Prednisone	30-50mg/day X2 weeks (for trial or tx of acute exacerbation) Chronic tx dose ideally <10mg EOD	♦majority of pts do not benefit (only 10-20% of stable pts will respond**) ♦for long-term tx, use inhaled steroids to ↓adverse effects	
If steroid responder**,	Inhaled Corticosteroids	Budesonide <i>Pulmicort</i>	200-400ug BID	♦some current controversy over the benefit of corticosteroids in COPD [#]	
		Fluticasone MDI <i>Flovent</i>	125-500ug BID		
		Fluticasone Diskus <i>Flovent</i>	100-500ug BID		
	Combination	Fluticasone (100,250,500ug) + Salmeterol (50ug) Diskus <i>Advair</i>	1 inhal BID		
Immunization for influenza and pneumococcus should be <u>considered</u> for all elderly & chronically ill patients	Influenza Vaccine		IM annually in fall	♦contraindicated if allergy to eggs or thimerosal	
	Pneumococcal Vaccine		IM once in a lifetime; revaccination (5+ ys) may be indicated in some cases. ⁱⁱ	♦contraindicated in allergy, children <2yrs, & pregnancy/lactation	

DI = drug interactions; SABA=short acting beta 2 agonists; LABA=long acting beta 2 agonists; MDI=metered dose inhaler; DPI = dry powder inhaler
*max dose limited by side effects; doses may exceed maximums recommended in CPS.

** steroid responder = if improvement in post bronchodilator FEV1 value > 20% and at least 200ml increase is observed following prednisone trial; all attempts should be made to use inhaled steroids vs. oral for chronic therapy to ↓ systemic side effects

ISOLDE study found fluticasone 1000ug/d beneficial over 6 months (↓ rate of decline in mod-severe COPD)ⁱⁱⁱ

ⁱ Guidelines for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). The Canadian Respiratory Review Panel, Nov, 1998.

ⁱⁱ Centers for Disease Control (CDC) Guidelines

ⁱⁱⁱ Burge PS. EUROSCOP, ISOLDE and the Copenhagen City Lung Study. Thorax 1999;54:287-288.